Ozmosi | 177Lu-rhPSMA-10.1 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

177Lu-rhPSMA-10.1

Alternative Names: 177Lu-rhPSMA-10.1
Clinical Status: Active
Latest Update: 2026-01-15
Latest Update Note: News Article

Product Description

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Blue Earth Therapeutics
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 177Lu-rhPSMA-10.1

Countries in Clinic: Belgium, Germany, Netherlands, United States

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Prostate Cancer|Prostatic Diseases|Urogenital Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05413850

 BET-PSMA-121

P2

Recruiting

Urogenital Cancer|Prostate Cancer|Prostatic Diseases

2026-08-27

2%

2025-03-18

Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments

2022-002407-37

 2022-002407-37

P2

Active, not recruiting

Prostate Cancer

2028-07-05

2024-511537-35-00

 BET-PSMA-121

P2

Recruiting

Prostate Cancer

2028-03-31

2025-05-02

Treatments

Recent News Events

Date

Type

Title

01/15/2026

News Article

 First Patients in the UK Receive Doses of Blue Earth Therapeutics' Investigational Radiopharmaceutical Therapy Lutetium (177Lu) rhPSMA-10.1 Injection for Metastatic Castrate Resistant Prostate Cancer

10/07/2025

News Article

 Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose Intensification of Lutetium (177Lu) rhPSMA-10.1 Injection in mCRPC

05/01/2025

News Article

 Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer

03/13/2025

News Article

 Blue Earth Therapeutics Reports Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions